These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 35690130)

  • 1. First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure.
    Muller C; Tilloy V; Frobert E; Feghoul L; Garrigue I; Lepiller Q; Mirand A; Sidorov E; Hantz S; Alain S
    Antiviral Res; 2022 Aug; 204():105361. PubMed ID: 35690130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance.
    Chou S
    Antiviral Res; 2017 Dec; 148():1-4. PubMed ID: 29107686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical development of letermovir and maribavir: Overview of human cytomegalovirus drug resistance.
    Piret J; Boivin G
    Antiviral Res; 2019 Mar; 163():91-105. PubMed ID: 30690043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The human cytomegalovirus UL51 protein is essential for viral genome cleavage-packaging and interacts with the terminase subunits pUL56 and pUL89.
    Borst EM; Kleine-Albers J; Gabaev I; Babic M; Wagner K; Binz A; Degenhardt I; Kalesse M; Jonjic S; Bauerfeind R; Messerle M
    J Virol; 2013 Feb; 87(3):1720-32. PubMed ID: 23175377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The C-terminal part of the human cytomegalovirus terminase subunit pUL51 is central for terminase complex assembly.
    Neuber S; Wagner K; Messerle M; Borst EM
    J Gen Virol; 2018 Jan; 99(1):119-134. PubMed ID: 29205134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutual Interplay between the Human Cytomegalovirus Terminase Subunits pUL51, pUL56, and pUL89 Promotes Terminase Complex Formation.
    Neuber S; Wagner K; Goldner T; Lischka P; Steinbrueck L; Messerle M; Borst EM
    J Virol; 2017 Jun; 91(12):. PubMed ID: 28356534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products.
    Komatsu TE; Hodowanec AC; Colberg-Poley AM; Pikis A; Singer ME; O'Rear JJ; Donaldson EF
    Antiviral Res; 2019 Sep; 169():104549. PubMed ID: 31279814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds.
    Chou S
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28827420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient.
    Jung S; Michel M; Stamminger T; Michel D
    BMC Infect Dis; 2019 May; 19(1):388. PubMed ID: 31068147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phenotypes of cytomegalovirus genetic variants encountered in a letermovir clinical trial illustrate the importance of genotyping validation.
    Chou S; Watanabe J
    Antiviral Res; 2024 Aug; 228():105935. PubMed ID: 38880196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New Insights into Human Cytomegalovirus pUL52 Structure.
    Muller C; Alain S; Gourin C; Baumert TF; Ligat G; Hantz S
    Viruses; 2021 Aug; 13(8):. PubMed ID: 34452502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the terminase: An important step forward in the treatment and prophylaxis of human cytomegalovirus infections.
    Gentry BG; Bogner E; Drach JC
    Antiviral Res; 2019 Jan; 161():116-124. PubMed ID: 30472161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by
    Chou S; Satterwhite LE; Ercolani RJ
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29914965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance.
    Chou S
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6588-93. PubMed ID: 26259791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a leucine-zipper motif in pUL51 essential for HCMV replication and potential target for antiviral development.
    Muller C; Alain S; Hantz S
    Antiviral Res; 2023 Sep; 217():105673. PubMed ID: 37478917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing.
    Chou S; Kleiboeker S
    Antiviral Res; 2022 Nov; 207():105422. PubMed ID: 36170912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism.
    Pilorgé L; Burrel S; Aït-Arkoub Z; Agut H; Boutolleau D
    Antiviral Res; 2014 Nov; 111():8-12. PubMed ID: 25194992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of UL56 Mutations before Letermovir Therapy in Refractory Cytomegalovirus Transplant Recipients.
    Santos Bravo M; Tilloy V; Plault N; Palomino SS; Mosquera MM; Navarro Gabriel M; Fernández Avilés F; Suárez Lledó M; Rovira M; Moreno A; Linares L; Bodro M; Hantz S; Alain S; Marcos MÁ
    Microbiol Spectr; 2022 Apr; 10(2):e0019122. PubMed ID: 35343771
    [No Abstract]   [Full Text] [Related]  

  • 19. The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase.
    Goldner T; Hewlett G; Ettischer N; Ruebsamen-Schaeff H; Zimmermann H; Lischka P
    J Virol; 2011 Oct; 85(20):10884-93. PubMed ID: 21752907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure.
    Goldner T; Hempel C; Ruebsamen-Schaeff H; Zimmermann H; Lischka P
    Antimicrob Agents Chemother; 2014; 58(1):610-3. PubMed ID: 24189264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.